Research Radartracking 1,138 published studies · 277 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →

Bladder Cancer

A plain-English summary of the published research on Bladder Cancer, reviewed and approved by our editors — not a hand-curated clinical overview.

Research summary · reviewed
Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

Reviewed Jun 2026 · OncoForge editorial · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed· last updated Jun 2026

Evidence at a glanceHuman trial / meta-analysisMixed results⚠ Studies disagree
17 published studies that name Bladder Cancer2 human studies approved & graded (trial, observational, or meta-analysis)236 human clinical studies in the Bladder Cancer corpus1197 source documents in the Bladder Cancer corpus

last checked June 14, 2026

Why this grade?

Human trial / meta-analysis — Includes human trial or meta-analysis evidence.

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

What the guidelines say

NCI PDQESMONCCNASCO

We link the authoritative guidelines rather than reproduce them. Below, the treatments on this page are split into standard care, guideline or regulatory options, supportive care, and studied but not standard so established care is not mixed with experimental or supportive items.

Guideline / FDA options - context-specific
  • Pembrolizumab
Studied, not standard - investigational
  • adjuvant chemotherapy
  • carboplatin combination chemotherapy
  • Cisplatin-based chemotherapy
  • cisplatin-based neoadjuvant chemotherapy
  • cisplatin-containing combination chemotherapy
  • Gemcitabine and Docetaxel
  • Intravesical chemotherapy (immediate postoperative instillation)
  • Platinum-based chemotherapy
  • single-agent chemotherapy
  • vinflunine
  • Bacillus Calmette-Guérin (BCG)
  • intravesical bacillus Calmette-Guérin (BCG)
  • Enhanced recovery after surgery (ERAS) protocol
  • Multi-modal bladder-preserving therapy
  • multimodality bladder-preserving treatment
  • Bladder photodynamic diagnosis
  • CT-Urography with chest CT
  • cystoscopy
  • Enhanced cystoscopy
  • Enterocystoplasty
  • laparoscopic radical cystectomy
  • Multiparametric pelvic MRI
  • open radical cystectomy
  • open radical cystectomy with an extended lymph node dissection (LND)
  • orthotopic bladder substitute
  • Pelvic lymphadenectomy
  • radical cystectomy
  • Radical cystectomy with pelvic lymph node dissection
  • robot-assisted radical cystectomy
  • Second TURBT (repeat transurethral resection)
  • Transileal cutaneous ureterostomy
  • transurethral resection of the prostate
  • Enfortumab vedotin
  • Genistein

Read the guidelines

Cancer-specific deep links aren’t curated yet — these search the authoritative sources for Bladder Cancer.

Treatment map: Bladder Cancer

Open as a full page →

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

36
Interventions
0
Standard of care
20
Tested in people
1
Lab / animal
13
Named in lit.
5
Classes
Standard of care (0) Guideline option (2) Tested in people (20) Lab / animal only (1) Named in the literature (13)

Tested in people, by trial phase: phase not reported ×20

Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Surgery & procedures
—
—
12
—
5
Chemotherapy
—
—
4
—
6
Targeted therapy
—
—
1
—
—
Immunotherapy
—
2
2
—
—
Other
—
—
1
1
2

Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.

Established care — detail (2)
Immunotherapy
PembrolizumabFirst-line (advanced disease)
FDA-approved for this cancer.
—Guideline option
pembrolizumabDNA MMR (mismatch repair) deficiency, MSI-high or high TMB
FDA-approved for this cancer.
—Guideline option
Investigational & adjunct compounds — detail (34)
Meta-analysis (20)
Bacillus Calmette-Guérin (BCG)· MaintenanceBladder photodynamic diagnosisCisplatin-based chemotherapy· Neoadjuvant (before surgery)CT-Urography with chest CTcystoscopyEnfortumab vedotin· First-line (advanced disease)Enhanced recovery after surgery (ERAS) protocol· Adjuvant (after surgery)EnterocystoplastyGemcitabine and Docetaxelintravesical bacillus Calmette-Guérin (BCG)Intravesical chemotherapy (immediate postoperative instillation)· Adjuvant (after surgery)laparoscopic radical cystectomy· Adjuvant (after surgery)Multiparametric pelvic MRIopen radical cystectomyPlatinum-based chemotherapy· Recurrent or later-lineRadical cystectomy with pelvic lymph node dissectionrobot-assisted radical cystectomySecond TURBT (repeat transurethral resection)Transileal cutaneous ureterostomytransurethral resection of the prostate
Named in the literature
adjuvant chemotherapy· Adjuvant (after surgery)carboplatin combination chemotherapycisplatin-based neoadjuvant chemotherapy· Neoadjuvant (before surgery)cisplatin-containing combination chemotherapysingle-agent chemotherapyvinflunine· Recurrent or later-lineMulti-modal bladder-preserving therapymultimodality bladder-preserving treatmentEnhanced cystoscopyopen radical cystectomy with an extended lymph node dissection (LND)orthotopic bladder substitutePelvic lymphadenectomyradical cystectomy
Lab / animal only
Genistein

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.

Reported figures

Get cited updates on Bladder Cancer
A monthly email when the research changes — $10/mo. Manage follows
Follow Bladder Cancer

Snapshot

The essentials in ~60 seconds — every line is drawn from the cited sources below.

What it is
Bladder cancer is commonly divided into non‑muscle‑invasive, muscle‑invasive nonmetastatic, and metastatic disease, and most cases are non‑muscle‑invasive. Urothelial carcinoma is the most common subtype. [1][2][3][4]
Survival
Muscle‑invasive bladder cancer carries a significant risk of death and represents approximately 25% of bladder cancer diagnoses. [5]
Standard treatment
Radical cystectomy with standard or extended pelvic lymph node dissection is the standard approach for nonmetastatic muscle‑invasive and localized invasive bladder cancer and remains the treatment of choice for treatment failures in NMIBC and for T2‑T4aN0M0 disease. Neoadjuvant cisplatin‑based chemotherapy is recommended for fit patients and is recommended to be discussed because it is described as improving overall survival. [6][7][8]
Key test
Testing for DNA mismatch repair (MMR)/MSI status, tumour mutational burden (TMB), and PD‑L1 can identify patients likely to respond to immune checkpoint inhibitors; pembrolizumab has approval for unresectable or metastatic solid tumours with MMR deficiency, MSI‑high, or high TMB after progression on at least one systemic treatment. [4]
Biggest challenge
The main clinical challenges are the risk of recurrence and progression after initial treatment and uncertainties about the optimal frequency and duration of cystoscopic surveillance. [9][2]

Ask about Bladder Cancer

Answers come only from the cited sources on this page — with the supporting evidence shown. If the sources here don't cover your question, it will say so. Educational information, not medical advice.

Key numbers & factors

Risk factors

  • ▲ increases riskTobacco smoking [8][1]
  • ▲ increases riskWork‑related carcinogens [8]
  • ▲ increases riskArsenic exposure (high vs low) — top vs bottom tertile comparison [10]
  • ◆ mixedSecond‑hand smoke (SHS) exposure — Meta-analysis pooled RR 1.16 (95% CI: 0.95–1.43) among nonsmokers; stratified RRs 1.35 in males and 1.31 in females; limited evidence [11]
  • ▲ increases riskArsenic, cadmium, chromium, nickel (IARC group 1 metals) — IARC classified these as group 1 carcinogens; arsenic has sufficient evidence for bladder cancer in studies of high‑level exposure [10]

Biomarkers

  • MMR deficiency (dMMR)Actionablepredictive marker of immune checkpoint inhibitor response (pembrolizumab approval for dMMR/MSI‑high/high TMB) [4]
  • MSI‑highActionablepredictive marker of immune checkpoint inhibitor response (pembrolizumab approval for dMMR/MSI‑high/high TMB) [4]
  • High tumour mutational burden (TMB)Actionablepredictive marker of immune checkpoint inhibitor response (pembrolizumab approval for dMMR/MSI‑high/high TMB) [4]
  • PD‑L1Actionablepredictive marker of immune checkpoint inhibitor response [4]
  • Urine cytology · useful for diagnosis of high‑grade tumour recurrence [12]
  • TERT promoter mutations · high prevalence in urothelial carcinoma and urothelial carcinoma with glandular differentiation [4]
  • TP53 mutation · frequently mutated in urachal carcinoma and primary bladder adenocarcinoma [4]

10 sections — tap any heading to expand its cited detail. Key points are above.

OverviewBladder cancer is commonly classified as non-muscle-invasive, muscle-invasive nonmetastatic, or metastatic disease; non-muscle-invasive disease accounts for the majority of cases. Urothelial carcinoma is the most common subtype (more than 90% of cases), and bladder cancer is the fourth most common cancer in the United States.5 points
  • Clinical classification of bladder cancer is commonly divided into three categories—non-muscle-invasive, muscle-invasive nonmetastatic, and metastatic disease—which differ in prognosis, management, and therapeutic aims; non-muscle-invasive bladder cancer accounts for the majority of cases. [1][2]
  • Bladder cancer is the fourth most common cancer in the United States, and urothelial carcinoma is the most common subtype. [3][4]
  • Cystoscopy is the standard method for follow-up of non-muscle-invasive bladder cancer; a systematic review of surveillance schedules included 8 articles and the studies included a total of 30,600 patients, but uncertainties remain about optimal frequency and duration of surveillance. [2]
  • Pure adenocarcinomas of the bladder are rare and represent less than 2% of all bladder cancers. [4]
  • Surgical treatments differ between primary bladder adenocarcinoma (PBAC) and urachal carcinoma (UrC): radical cystectomy is recommended for PBAC, while partial cystectomy with excision of the median umbilical ligament and umbilicus is preferred for UrC. [4]
EpidemiologyBladder cancer is a common cancer—among the more common cancers in the United States and the 10 th most frequently diagnosed cancer worldwide. Major risk factors include tobacco smoking and occupational carcinogens, and higher arsenic exposure has also been associated with increased risk.6 points

Key figures

Prognostic factors
FactorEffectHR (95% CI)p
RR, top vs bottom tertile▲ worse1.6 (1.13–2.27)< .001 for heterogeneity
RR in males▲ worse1.35 (0.86–2.13)—
RR in females▲ worse1.31 (0.98–1.73)—
pooled relative risk for SHS exposure▲ worse1.16 (0.95–1.43)—
Source quotes
  • “Arsenic level was also associated with an increased risk of bladder cancer (RR, 1.60; 95% CI, 1.13-2.27; I2 = 76.0%; P < .001 for heterogeneity)”
  • “Stratified analyses by sex showed no differences in risk of bladder cancer by sex, with an RR of 1.35 (95% CI: 0.86-2.13) in males and 1.31 (95% CI: 0.98-1.73) in females.”
  • “The overall pooled RR of bladder cancer for SHS exposure was 1.16 [95% confidence interval (CI): 0.95-1.43]”
  • Bladder cancer is the 10 th most frequently diagnosed cancer worldwide. [11]
  • The most common urologic cancers are prostate, kidney, and bladder. [10]
  • Higher arsenic exposure has been associated with an increased risk of bladder cancer (top vs bottom tertile comparison). [10]
  • Bladder cancer is among the more common cancers in the United States. [1]
  • Smoking and work-related carcinogens are described as the most important risk factors for bladder cancer. [8]
  • While tobacco smoking is a well-established risk factor for bladder cancer, the association between second-hand smoke (SHS) exposure and bladder cancer remains less clear: a meta-analysis that included twelve studies (eight case-control and four cohort), involving approximately 1200 bladder cancer cases, reported an overall pooled relative risk (RR) of bladder cancer for second-hand smoke exposure of 1.16 (95% CI: 0.95-1.43) among nonsmokers; stratified analyses by sex showed RRs of 1.35 (95% CI: 0.86-2.13) in males and 1.31 (95% CI: 0.98-1.73) in females, higher risks were observed in studies conducted in Africa and Asia, and the authors noted a relatively limited number of cases and studies and called for further research with greater statistical power and improved exposure assessment. [11]
Key biomarkersSeveral tissue and blood/urine biomarkers are used or under discussion in bladder cancer, including TMB, MSI, MMR, PD-L1, and TERT promoter mutations, and guideline statements on urine markers have recently been updated. Molecular profiling may help direct therapy by matching treatments to tumor-specific mechanisms and targets, and the PD-1 inhibitor pembrolizumab has a tumor-agnostic approval tied to certain genomic biomarkers.8 points
  • Recent guideline updates included changes to statements on urine markers after diagnosis of bladder cancer. [13]
  • Urine cytology is reported to be useful for the diagnosis of high-grade tumor recurrence. [12]
  • The sources state that molecular medicine may improve clinical outcomes by directing therapy toward mechanisms and targets associated with an individual patient's tumor. [12]
  • The PD-1 inhibitor pembrolizumab was approved as the first tumor-agnostic treatment for unresectable or metastatic solid tumors with DNA MMR deficiency, MSI-high, or high TMB after progression on at least one systemic treatment. [4]
  • TMB, MSI, MMR and PD-L1 are known predictive markers of immune checkpoint inhibitor response. [4]
  • In urachal carcinoma (UrC), the top 10 mutated genes included TP53 (79%), KRAS (34%), SMAD4 (21%), DICER1 (15%), MYC (14%), GNAS (13%), LRP1B (11%), APC (10%), NF1 (9%), and ARID1A (8%). [4]
  • In primary bladder adenocarcinoma (PBAC), the top 10 frequently affected genes included TP53 (77%), KRAS (17%), SMAD4 (14%), TERT (14% overall when coding and promoter region data are combined), MYC (13%), CDKN2A (13%), ARID1A (11%), PI3KCA (9%), APC (8%) and FGF19 (8%). [4]
  • TERT promoter mutations have a high prevalence in urothelial carcinoma (UC) and urothelial carcinoma with glandular differentiation (UCg). [4]
Standard managementManagement depends on stage: non‑muscle‑invasive disease is established after complete, deep transurethral resection with risk stratification (EORTC) guiding intravesical therapies, while nonmetastatic muscle‑invasive and localized invasive disease are generally managed with radical cystectomy and lymph node dissection. Neoadjuvant cisplatin‑based chemotherapy is recommended for suitable/fit patients and current advice limits adjuvant chemotherapy to use within clinical trials.15 points
  • Radical cystectomy combined with standard or extended pelvic lymph node dissection (removal of the bladder including regional lymph nodes) is described as the standard treatment for nonmetastatic muscle‑invasive and localized invasive bladder cancer and is stated to remain the treatment of choice for treatment failures in NMIBC and for T2‑T4aN0M0 disease. [6][8][7]3 sources
  • Neoadjuvant cisplatin‑based chemotherapy is recommended for patients in suitable general health with satisfactory renal function (fit patients) and is recommended to be discussed because it is described as improving overall survival. [6][8]
  • An orthotopic bladder substitute/enterocystoplasty is an option to offer to both male and female patients lacking contraindications and when urethral recutting is negative on extemporaneous examination; when enterocystoplasty is not appropriate, transileal cutaneous ureterostomy is recommended as the method of urinary diversion. [6][7]
  • The diagnosis of non‑muscle‑invasive bladder cancer (Ta, T1, or CIS) is made after complete and deep tumour resection; bladder photodynamic (enhanced) diagnosis and performing a second TURBT 4 to 6 weeks later can improve the initial diagnosis. [9]
  • Risk of recurrence and/or tumour progression in NMIBC is assessed using the EORTC score, and patients are stratified to guide adjuvant options such as intravesical chemotherapy, BCG, or cystectomy for unresponsive disease. [9]
  • Enhanced cystoscopy (photodynamic diagnosis) was among the topics with updated statements in the recent NMIBC guideline amendment. [13]
  • Performing the first cystoscopy within 3–4 months after transurethral resection of the bladder showed better outcomes, while excessively early or delayed cystoscopy procedures were reported to increase the risk of recurrence and progression. [2]
  • In low‑risk patients some studies support discontinuing surveillance after 5 years without recurrence, whereas other studies recommend prolonging surveillance in patients with risk factors such as smoking or multiple tumours. [2]
  • CT‑Urography coupled with chest CT scans is used to assess the extent of muscle‑invasive bladder cancer, and multiparametric pelvic MRI may be an alternative imaging approach. [6]
  • Current advice recommends the use of adjuvant chemotherapy only within clinical trials. [7]
  • Guideline updates have addressed neoadjuvant and adjuvant chemotherapy, radical cystectomy, pelvic lymphadenectomy, and multi‑modal bladder‑preserving therapy. [5]
  • All patients undergoing surgery should be included in an enhanced recovery after surgery (ERAS) protocol. [6]
  • Multimodality treatment is noted as an alternative for selected, well‑informed, and compliant patients when cystectomy is not an option. [8]
  • For patients with metastatic disease, cisplatin‑containing combination chemotherapy is recommended; for unfit patients, carboplatin‑containing combination chemotherapy or single agents are described as options. [8]
  • Compared with open radical cystectomy, minimally invasive techniques (laparoscopic and robot‑assisted radical cystectomy) were associated with reduced intraoperative blood loss and lower transfusion rates but required longer operative time; laparoscopic radical cystectomy was associated with a potentially greater likelihood of enhanced postoperative recovery and fewer complications though the evidence is limited and heterogeneous, robot‑assisted radical cystectomy did not demonstrate consistent superiority over laparoscopy in perioperative measures, and short‑term oncological surrogate outcomes were similar across open, laparoscopic, and robot‑assisted approaches. [14]
Treatments & compounds studied35 therapeutic or management items are reported across chemotherapy, immunotherapy, procedural/device, and other categories (including surgical and diagnostic approaches).35 treatments

Chemotherapy

  • adjuvant chemotherapy: Adjuvant (after surgery)Adjuvant chemotherapy is recommended to be used only within clinical trials according to the guidelines. [7]
  • carboplatin combination chemotherapy: For unfit patients, carboplatin combination chemotherapy is described as an option. [8]
  • Cisplatin-based chemotherapy · 3 findings
    • Neoadjuvant (before surgery)Neoadjuvant cisplatin-based chemotherapy is recommended for patients who are in good general health with satisfactory renal function. [6]
    • Neoadjuvant (before surgery)For fit patients, cisplatin-based neoadjuvant chemotherapy is reported to improve overall survival and should be discussed. [8]
    • Cisplatin-containing combination chemotherapy is recommended for patients with metastatic disease. [8]
  • Gemcitabine and Docetaxel: In high-risk BCG-naïve NMIBC, intravesical gemcitabine plus docetaxel showed a 24-month recurrence-free survival of 78% (95% CI 70%–84%); in direct comparisons versus BCG, RFS did not differ significantly (HR 0.87, 95% CI 0.51–1.50). [15]
    24-month recurrence-free survival 78% (95% CI 70–84)24-month recurrence-free survival 41% (95% CI 34–47)Grade 60; 3 adverse event rate 3.6%
    Source quotes
    • “In high-risk BCG-naïve and BCG-treated (BCG-exposed/-unresponsive) NMIBC, Gem/Doce resulted in 24-month RFS of 78% (95% confidence intervals [CI] 70%-84%) and 41% (95% CI: 34%-47%), and 24-month PFS of 97% (95% CI: 69%-100%) and 85% (95% CI: 63%-95%), respectively.”
    • “In high-risk BCG-naïve and BCG-treated (BCG-exposed/-unresponsive) NMIBC, Gem/Doce resulted in 24-month RFS of 78% (95% confidence intervals [CI] 70%-84%) and 41% (95% CI: 34%-47%), and 24-month PFS of 97% (95% CI: 69%-100%) and 85% (95% CI: 63%-95%), respectively.”
    • “Grade 60; 3 AEs were found in 3.6% of Gem/Doce cohorts.”
  • Intravesical chemotherapy (immediate postoperative instillation): Adjuvant (after surgery)Immediate postoperative endovesical instillations of intravesical chemotherapy are described as an adjuvant regimen in NMIBC risk-stratified management. [9]
  • Platinum-based chemotherapy: Recurrent or later-lineSecond-line treatment with platinum-based chemotherapy is stated as recommended in the guideline summary. [6]
  • single-agent chemotherapy: For unfit patients, single-agent chemotherapy is described as an option. [8]
  • vinflunine: Recurrent or later-lineVinflunine is described as a new, approved option for second-line chemotherapy in metastatic disease. [7]

Targeted therapy

  • Enfortumab vedotin: First-line (advanced disease)A guideline recommends enfortumab vedotin together with pembrolizumab as a first-line option for metastatic muscle-invasive bladder cancer. [6]

Immunotherapy

  • Bacillus Calmette-Guérin (BCG): MaintenanceIntravesical Bacillus Calmette-Guérin (BCG) is recommended as an induction and maintenance intravesical therapy in guideline-recommended adjuvant strategies for NMIBC. [9]
  • intravesical bacillus Calmette-Guérin (BCG): Noninvasive urothelial carcinoma including carcinoma in situ of the prostate is stated to be treated with intravesical bacillus Calmette-Guérin (BCG) following endoscopic resection. [16]
  • Pembrolizumab · 2 findings
    • First-line (advanced disease)Pembrolizumab is recommended alongside enfortumab vedotin as a first-line option for metastatic muscle-invasive bladder cancer in the cited guideline. [6]
    • DNA MMR (mismatch repair) deficiency, MSI-high or high TMBPembrolizumab is approved as a tumor-agnostic immunotherapy option for unresectable or metastatic solid tumors with DNA mismatch repair deficiency, MSI-high, or high tumor mutational burden. [4]

Procedures & devices

  • Bladder photodynamic diagnosis: Bladder photodynamic diagnosis is reported as a tool that can help to improve the initial diagnosis of NMIBC. [9]
  • CT-Urography with chest CT: CT-Urography with chest CT is used for staging workup in muscle-invasive disease. [6]
  • cystoscopy: Cystoscopy is used as the standard surveillance procedure in NMIBC follow-up, though the optimal frequency and duration are uncertain. [2]
  • Enhanced cystoscopy: Enhanced cystoscopy is among the diagnostic/management topics addressed in recent NMIBC guideline updates. [13]
  • Enterocystoplasty: Enterocystoplasty is proposed as a urinary diversion option when appropriate after cystectomy. [6]
  • laparoscopic radical cystectomy: Adjuvant (after surgery)Laparoscopic radical cystectomy was associated with reduced intraoperative blood loss, lower transfusion rates, and a potentially greater likelihood of enhanced postoperative recovery and fewer complications compared with open surgery. [14]
  • Multiparametric pelvic MRI: Multiparametric pelvic MRI is presented as a potential alternative imaging modality in MIBC staging. [6]
  • open radical cystectomy: Open radical cystectomy was one of the surgical approaches assessed and short-term oncological outcomes were reported to be similar across approaches. [14]
  • open radical cystectomy with an extended lymph node dissection (LND): Open radical cystectomy with an extended lymph node dissection (LND) is stated to remain the treatment of choice for treatment failures in non-muscle-invasive bladder cancer and for T2-T4aN0M0 disease. [8]
  • orthotopic bladder substitute: An orthotopic bladder substitute is reported to be an option that should be offered to both male and female patients lacking contraindications. [7]
  • Pelvic lymphadenectomy: Pelvic lymphadenectomy is discussed in recent guideline updates as part of surgical management. [5]
  • radical cystectomy: Radical cystectomy (RC) is described as the basic treatment of choice in localized invasive disease for both sexes. [7]
  • Radical cystectomy with pelvic lymph node dissection: Radical cystectomy combined with standard pelvic lymph node dissection is a standard surgical treatment option for nonmetastatic muscle-invasive bladder cancer. [6]
  • robot-assisted radical cystectomy: Robot-assisted radical cystectomy did not show consistent superiority over laparoscopy in perioperative measures. [14]
  • Second TURBT (repeat transurethral resection): A second transurethral resection of the bladder (second TURBT) at 4 to 6 weeks is indicated in some patients to improve initial NMIBC diagnosis. [9]
  • Transileal cutaneous ureterostomy: Transileal cutaneous ureterostomy is recommended as the urinary diversion method when enterocystoplasty is not suitable. [6]
  • transurethral resection of the prostate: Transurethral resection of the prostate is reported to potentially improve contact of BCG with the prostatic urethra and to appear to increase BCG response rates in Noninvasive UC including CIS of the prostate. [16]

Other

  • Enhanced recovery after surgery (ERAS) protocol: Adjuvant (after surgery)Enhanced recovery after surgery (ERAS) protocols are recommended for all patients undergoing bladder cancer surgery. [6]
  • Multi-modal bladder-preserving therapy: Multimodal bladder-preserving therapy is a management approach highlighted in guideline updates. [5]
  • multimodality bladder-preserving treatment: Multimodality bladder-preserving treatment in localized disease is described as an alternative for selected, well-informed, and compliant patients for whom cystectomy is not considered. [7]
Staging & riskNon-muscle-invasive bladder cancer includes Ta, T1, and carcinoma in situ (CIS). Staging of muscle-invasive disease relies on imaging (commonly CT urography with chest CT; MRI, including multiparametric pelvic MRI, can assess local extent) and evaluation of the lower urinary tract is performed with white-light cystoscopy (with fluorescence-aided cystoscopy and narrow-band imaging as adjuncts); CT is preferred for pulmonary assessment.3 points
  • Guidelines recommend imaging for staging of muscle-invasive bladder cancer, typically CT urography with chest CT; MRI (including multiparametric pelvic MRI) can be used to assess local extent, and computed tomography is preferred for pulmonary evaluation. [6][8]
  • Non-muscle-invasive bladder cancer includes Ta, T1, and carcinoma in situ (CIS) presentations. [9]
  • White-light cystoscopy is the gold standard for evaluation of the lower urinary tract and is described as the most cost-effective method to detect recurrence of bladder cancer; fluorescence-aided cystoscopy and narrow-band imaging can aid evaluations as adjuncts. [12]
PrognosisPrognosis in bladder cancer varies by stage and specific pathological features: muscle-invasive disease (approximately 25% of diagnoses) carries a significant risk of death, while stromal invasion by urothelial carcinoma of the prostate is associated with a poor prognosis. Risk stratification tools such as the EORTC score are used for recurrence and progression risk in NMIBC, and evidence finds comparable short-term surrogate oncological endpoints between minimally invasive and open radical cystectomy approaches while long-term outcomes remain uncertain; in high-risk patients different surveillance schedules showed no differences in mortality or progression.5 points
  • The EORTC score is used to assess the risk of recurrence and/or tumour progression in NMIBC. [9]
  • Muscle-invasive bladder cancer carries a significant risk of death and represents approximately 25% of bladder cancer diagnoses. [5]
  • Stromal invasion by urothelial carcinoma of the prostate is stated to carry a poor prognosis. [16]
  • Short-term surrogate oncological endpoints after radical cystectomy approaches appeared comparable between minimally invasive and open surgery, but long-term outcomes remain to be determined. [14]
  • In high-risk patients, across the different surveillance schedules analysed, no differences were found in terms of mortality or progression. [2]
What we don't know yetSeveral evidence gaps remain in bladder cancer care, including limits in the underlying evidence cited by guidelines, lack of high-level data for rare histologies, uncertainties about optimal surveillance and long-term surgical outcomes, heterogeneity in maintenance chemotherapy data, and incomplete understanding of some environmental and second‑hand smoke exposures. Guideline authors and study authors call for prospective, long-term, and better‑powered studies to address these gaps.7 points
  • Guideline authors note limitations in the evidence base and state that future studies are essential to refine recommendations and improve patient care; recommendations were developed by balancing evidence quality, benefits and harms, and patient values. [13][17]
  • Prospective clinical trials often exclude rare histological types such as PBAC and UrC, leading to a lack of high-level evidence and established systemic therapeutic recommendations for these subtypes. [4]
  • The effects of low-level environmental exposure to nonessential elements on urologic cancer risk remain poorly understood. [10]
  • Maintenance effects reported for Gem/Doce were derived from between-study comparisons and should be interpreted cautiously due to heterogeneity in maintenance protocols and adherence. [15]
  • Long-term oncological outcomes after minimally invasive versus open radical cystectomy remain to be determined. [14]
  • There are uncertainties regarding the optimal frequency and duration of cystoscopic surveillance after initial surgery for NMIBC; prospective and long-term studies are required to define optimal surveillance schedules, to optimise resources, and to reduce the burden on patients. [2]
  • For the association between second-hand smoke and bladder cancer, authors call for further research with greater statistical power and improved exposure assessment to better clarify the role of second‑hand smoke exposure. [11]
Safety & interactionsGuidelines recommend using comorbidity rather than age when deciding on radical cystectomy. The International Agency for Research on Cancer classifies arsenic, cadmium, chromium, and nickel as group 1 carcinogens, and identifies arsenic as a bladder carcinogen with sufficient evidence in humans from studies of high-level environmental or occupational exposure.2 points
  • The guidelines state that comorbidity, rather than age, should be used when deciding on radical cystectomy. [8]
  • The International Agency for Research on Cancer has classified arsenic, cadmium, chromium, and nickel as group 1 carcinogens; arsenic is identified as a carcinogen for bladder cancer with sufficient evidence in humans in studies of high-level environmental or occupational exposure. [10]
Biology & pathwaysThese adenocarcinomas frequently harbor mutations in cell membrane receptor genes that have been identified as potential molecular targets for personalized therapy. Urachal carcinoma (UrC) and primary bladder adenocarcinoma (PBAC) show similar mutational profiles, sharing 15 of their top 30 most frequently affected genes.2 points
  • Many cell membrane receptor genes are mutated in these adenocarcinomas and are identified as potential molecular targets for personalized therapy. [4]
  • Urachal carcinoma (UrC) and primary bladder adenocarcinoma (PBAC) have similar mutational profiles, with 15 of their top 30 most frequently affected genes overlapping. [4]

Common questions

What is Bladder Cancer?

Bladder cancer is commonly classified as non-muscle-invasive, muscle-invasive nonmetastatic, or metastatic disease; non-muscle-invasive disease accounts for the majority of cases. Urothelial carcinoma is the most common subtype (more than 90% of cases), and bladder cancer is the fourth most common cancer in the United States.

How common is Bladder Cancer?

Bladder cancer is a common cancer—among the more common cancers in the United States and the 10 th most frequently diagnosed cancer worldwide. Major risk factors include tobacco smoking and occupational carcinogens, and higher arsenic exposure has also been associated with increased risk.

Which biomarkers are important in Bladder Cancer?

Several tissue and blood/urine biomarkers are used or under discussion in bladder cancer, including TMB, MSI, MMR, PD-L1, and TERT promoter mutations, and guideline statements on urine markers have recently been updated. Molecular profiling may help direct therapy by matching treatments to tumor-specific mechanisms and targets, and the PD-1 inhibitor pembrolizumab has a tumor-agnostic approval tied to certain genomic biomarkers.

What is the biology of Bladder Cancer?

These adenocarcinomas frequently harbor mutations in cell membrane receptor genes that have been identified as potential molecular targets for personalized therapy. Urachal carcinoma (UrC) and primary bladder adenocarcinoma (PBAC) show similar mutational profiles, sharing 15 of their top 30 most frequently affected genes.

How is Bladder Cancer treated?

Management depends on stage: non‑muscle‑invasive disease is established after complete, deep transurethral resection with risk stratification (EORTC) guiding intravesical therapies, while nonmetastatic muscle‑invasive and localized invasive disease are generally managed with radical cystectomy and lymph node dissection. Neoadjuvant cisplatin‑based chemotherapy is recommended for suitable/fit patients and current advice limits adjuvant chemotherapy to use within clinical trials.

What treatments are studied for Bladder Cancer?

35 therapeutic or management items are reported across chemotherapy, immunotherapy, procedural/device, and other categories (including surgical and diagnostic approaches).

Sources

Every statement above is drawn from these reviewed sources. This page reports what they describe. Sources last checked June 14, 2026.

  1. GuidelineNCCN Guidelines® Insights: Bladder Cancer, Version 3.2024 · 2024
  2. Systematic reviewCurrent Evidence on the Use of Cystoscopy in the Follow-up of Non-Muscle-Invasive Bladder Cancer: Are We Overusing It? Systematic Review of the Literature · 2026
  3. GuidelineBladder cancer · 2013
  4. Systematic reviewGenetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses · 2026
  5. GuidelineTreatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024) · 2024
  6. GuidelineFrench AFU Cancer Committee Guidelines - Update 2024-2026: Muscle-invasive bladder cancer (MIBC) · 2024
  7. GuidelineTreatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines · 2011
  8. GuidelineEAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines · 2014
  9. GuidelineFrench AFU Cancer Committee Guidelines - Update 2024-2026: Non-muscle invasive bladder cancer (NMIBC) · 2024
  10. Meta-analysisEnvironmental Nonessential Element Exposure and Urologic Cancer: A Systematic Review and Meta-Analysis · 2026
  11. Meta-analysisSecond-hand smoke and bladder cancer risk among nonsmokers: a systematic review and a meta-analysis · 2026
  12. GuidelineICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers · 2013
  13. GuidelineDiagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment · 2024
  14. Meta-analysisComparative efficacy and safety of open, laparoscopic, and robot-assisted radical cystectomy: a systematic review and network meta-analysis · 2026
  15. Meta-analysisEfficacy and Safety of Intravesical Gemcitabine and Docetaxel Combination Therapy in Patients With Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis · 2026
  16. GuidelineICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial carcinoma of the prostate · 2013
  17. GuidelineEuropean Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update · 2024

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
36
Meta-analysis
182
Systematic review
34
Randomized trial
2
Clinical trial
15
Observational
4
Case report
35
Review
885
Preclinical
0
Other
4

Living document — last change June 14, 2026: Cancer page updated. 2 recent updates logged.

Medicines & supplements studied for Bladder Cancer

PubMedFDAClinicalTrials.gov

Every drug, supplement, and other agent the published studies cover for Bladder Cancer, ranked by how strong the evidence is — what studies report, not a recommendation. Tap any to see its full profile.

Medicines · 1

GenisteinInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Biological activities and therapeutic potential of soy isoflavones: a focus on anticancer activity

No human studies yet · No numeric effect sizes reported · Based on a single study.
Other1 studyFull profile →

What recent studies report in Bladder Cancer

These are reviewed studies whose abstracts concern Bladder Cancer. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Bladder Cancer. Most are early lab, animal, or small human studies, and findings often conflict.

17 studies2 human⚠ Conflicting evidenceMechanism (6)Trial (1)Supportive care (1)

Tracking 17 published studies of Bladder Cancer: 2 in humans, 15 reviews/other.

Reported direction across studies: 7 positive, 3 mixed, 7 inconclusive.

Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.

These counts summarize what the studies reported; they are not a measure of whether anything works for Bladder Cancer.

Compounds with studies mentioning Bladder Cancer

Genistein (1)
ReviewReported positivePreclinical onlyTier 1 · lab

Biological activities and therapeutic potential of soy isoflavones: a focus on anticancer activity

Molecular biology reports · May 2026 · narrative review

Genisteinbreast cancerovarian cancerprostate cancergliomaneuroblastomahepatocellular carcinomalung cancerbladder cancerosteosarcomarhabdomyosarcoma

This is a narrative review of the biological activities and potential therapeutic roles of soy isoflavones (including genistein and daidzein). The authors summarize proposed anticancer mechanisms (estrogen receptor modulation, apoptosis, anti-angiogenesis, epigenetic effects, etc.) and report that in vitro and in vivo studies have shown promising results across a range of tumor types. They conclude that further research—especially studies combining isoflavones with established chemotherapeutics—is needed.

Studied with: chemotherapeutic agents.

Key findings
  • Soy isoflavones (genistein, daidzein) have estrogenic and non-estrogenic activities including anti-inflammatory, antioxidant, and immunomodulatory effects.
  • Proposed anticancer mechanisms include modulation of estrogen receptors, copper ion-dependent induction of cell death, promotion of apoptosis, inhibition of angiogenesis and metastasis, regulation of epigenetic processes, and effects on platelet function.
  • Because of estrogen receptor interactions, isoflavones have been studied particularly in hormone-dependent cancers such as breast, ovarian, and prostate cancer.
  • In vitro and in vivo studies have reported promising results in multiple malignancies (gliomas, neuroblastoma, hepatocellular carcinoma, lung and bladder cancers, osteosarcoma, rhabdomyosarcoma).
  • Authors recommend further investigation, particularly combining isoflavones with established chemotherapeutics, to evaluate potential synergy.
Limitations: This article is a narrative review and does not present new clinical trial data.; The evidence summarized is primarily preclinical (in vitro and in vivo) with no clinical trial data provided in the abstract.; Mechanistic proposals are not proven clinical effects and require further experimental and clinical validation.; Safety and efficacy in patients, optimal dosing, and interactions with standard therapies are not established in this review..

AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewInconclusiveLimited evidenceTier 4 · clinical

Bladder cancer: An Update

Nursing · Apr 2024

bladder cancerurothelial cell carcinoma

This article is a clinical update on bladder cancer that summarizes risk factors, clinical presentation, and treatment strategies. It states that bladder cancer is the 10th most common cancer globally and primarily manifests as urothelial cell carcinoma. The authors emphasize the importance of comprehensive nursing support and patient education. The abstract does not present original data or quantitative study results.

Key findings
  • Bladder cancer is the 10th most common cancer globally.
  • Bladder cancer primarily manifests as urothelial cell carcinoma.
  • Risk factors involve acquired genetic mutations and congenital predispositions.
  • The article discusses risk factors, clinical presentation, and treatment strategies.
  • Emphasis is placed on providing comprehensive nursing support and patient education.
Limitations: Review article / update rather than original research; no primary data reported in the abstract.; Abstract provides no methods, search strategy, or inclusion/exclusion criteria.; No sample size, quantitative outcomes, or statistical results are reported in the abstract.; Not focused on any specific repurposed drug or natural compound..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewMechanismReported positiveLimited evidenceTier 4 · clinical

CD44 in Bladder Cancer

Cancers · Mar 2024 · PDQ cancer information summary (narrative review)

bladder cancer

This PDQ cancer information summary reviews the glycoprotein CD44 and its many isoforms and carbohydrate variations, describing its diverse cellular functions. The summary states that CD44 is involved in cancer progression and metastasis and identifies CD44 as a strong therapeutic target in many cancers, including bladder cancer.

Key findings
  • CD44 is a glycoprotein with many isoforms and variations in carbohydrate patterning that participates in a diverse set of cellular functions.
  • These features allow CD44 to play a role in normal and pathologic cellular processes, including cancer progression and metastasis.
  • CD44 is identified as a strong therapeutic target in many cancer types, including bladder cancer.
  • This document is a PDQ cancer information summary intended to inform patients, families, and caregivers and is maintained by Editorial Boards that review and update content regularly.
Limitations: This is a narrative PDQ summary/review and does not present original experimental or clinical trial data.; The abstract provides no methods, quantitative results, or specific study populations.; No clinical trial or primary study outcomes are reported in the abstract..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewInconclusiveLimited evidenceTier 4 · clinical

Gender, Bladder Cancer Healthcare and Burden of COVID-19

Cancer investigation · Jan 2023 · review

Supportive careurinary bladder neoplasmsbladder cancer

This review discusses how the COVID-19 pandemic has affected bladder cancer healthcare. The authors state that bladder cancer patients may be more susceptible to COVID-19 with higher mortality, note that the EAU recommended a comprehensive panel for diagnosis and treatment during the pandemic, and highlight concerns that investigation of COVID-19 treatments could lead to drug shortages. The paper focuses on EAU recommendations to provide a comprehensive panel for high-risk bladder cancer patients.

Key findings
  • The authors state bladder cancer may be a comorbid disease that is more susceptible to COVID-19 infection with higher mortality risk.
  • The European Association of Urology (EAU) recommended a comprehensive panel for bladder cancer diagnosis and treatment during the pandemic.
  • Urgent need for COVID-19 treatments has prompted evaluation of different medications, which may lead to drug shortages that could affect bladder cancer care.
  • This review focuses on the least recommendations of the EAU about bladder cancer during the COVID-19 pandemic to provide a comprehensive panel for high-risk patients.
Limitations: This is a review article and does not present original primary data.; Abstract provides no methods, quantitative results, or sample sizes.; Findings are descriptive and appear to summarize guidelines rather than report new empirical outcomes.; Scope appears limited to EAU recommendations per the abstract; applicability beyond that is not detailed..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewMechanismInconclusiveLimited evidenceTier 3 · early human

Liquid Biopsy in Bladder Cancer

Methods in molecular biology (Clifton, N.J.) · Jan 2023

bladder cancer

This article is a review that summarizes recent findings and issues related to liquid biopsy in bladder cancer. It focuses on circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), urinary tumor DNA, exosomes, and circulating RNA in blood and body fluids.

Key findings
  • The review discusses fluid biopsy approaches based on circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and circulating RNA.
  • Both blood-based and other body-fluid (urine) tumor-derived analytes are considered, with an emphasis on urinary tumor DNA for bladder cancer.
  • The article highlights recent findings and outstanding issues related to liquid biopsy in bladder cancer.
Limitations: Abstract contains no original quantitative data or methods details.; No information on search strategy, inclusion criteria, or how recent findings were selected is provided in the abstract.; Abstract does not provide performance metrics, sample sizes, or validation results for the discussed biomarkers..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewInconclusiveLimited evidenceTier 4 · clinical

Advances in Management of Bladder Cancer

Journal of clinical medicine · Dec 2021

bladder cancernon-muscle-infiltrating bladder cancer (NMIBC)muscle-infiltrating bladder cancer (MIBC)

This editorial/review addresses management of bladder cancer. It notes that bladder cancer presents as two distinct clinical entities — non-muscle-infiltrating (NMIBC) and muscle-infiltrating (MIBC). The abstract contains no original data or specific quantitative results.

Key findings
  • Bladder cancer is a complex disease with distinct presentations: NMIBC and MIBC.
Limitations: Editorial article with no original experimental or clinical data reported in the abstract.; Abstract text provided is minimal/truncated and contains no methods, results, or quantitative findings.; Cannot assess specific management recommendations or evidence strength from the abstract alone..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Meta-analysisReported positiveLimited evidenceTier 4 · clinicaln = 72

Red and processed meat consumption and cancer outcomes: Umbrella review

Food chemistry · Sep 2021 · umbrella review of systematic reviews and meta-analyses

overall cancer mortalitynon-Hodgkin lymphomabladder cancerbreast cancercolorectal cancerendometrial canceresophageal cancergastric cancerlung cancernasopharyngeal canceroral cavity canceroropharyngeal cancerprostate cancer

This umbrella review pooled and evaluated existing systematic reviews and meta-analyses on red and processed meat consumption and cancer outcomes. It identified associations between higher red and processed meat intake and increased risks of multiple cancer types, and dose-response analyses showed that each 100 g/day increase in red meat and each 50 g/day increase in processed meat were associated with higher risk ranges for various cancers. The authors report no evidence of benefit associated with increased consumption.

Reported effects: 100 g/d increment (red meat): 11%-51% higher risk · 50 g/d increment (processed meat): 8%-72% higher risk

Key findings
  • The umbrella review identified 72 meta-analyses covering multiple cancer outcomes for red and processed meat.
  • Red meat consumption was associated with increased risk of overall cancer mortality and multiple specific cancers including NHL, bladder, breast, colorectal, endometrial, esophageal, gastric, lung and nasopharyngeal cancers.
  • Processed meat consumption was associated with increased risk of overall cancer mortality and multiple cancers including NHL, bladder, breast, colorectal, esophageal, gastric, nasopharyngeal, oral cavity, oropharynx and prostate cancer.
  • Dose-response analyses reported that a 100 g/day increment in red meat was associated with 11%-51% higher risk and a 50 g/day increment in processed meat was associated with 8%-72% higher risk of multiple cancer outcomes.
Limitations: Findings derive from meta-analyses of observational studies; causality cannot be established and residual confounding is possible.; Heterogeneity across included meta-analyses and primary studies may affect pooled estimates.; Potential for publication bias and varying methodological quality of the underlying reviews and studies.; Umbrella review-level synthesis depends on the quality and reporting of the included systematic reviews and meta-analyses; details on primary-study designs and adjustments are not provided in this abstract..

AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewMechanismMixed resultsLimited evidenceTier 1 · lab

Nucleobindin-2/Nesfatin-1-A New Cancer Related Molecule?

International journal of molecular sciences · Aug 2021 · review

breast cancercolon cancerprostate cancerendometrial cancerthyroid cancerbladder cancerglioblastomaadrenocortical carcinomaovarian epithelial carcinoma

This review discusses nucleobindin-2/nesfatin-1 (NUCB2/NESF-1) as a cancer-related molecule. It summarizes reports that higher expression is linked with poorer outcomes and with increased cancer cell proliferation, migration, and invasion in several cancers, while other reports suggest it may inhibit growth in some cancer cell types. The article does not present new experimental data.

Key findings
  • High NUCB2/NESF-1 expression has been associated with poor outcomes in several cancers.
  • Reported effects include increased cell proliferation, migration, and invasion in breast, colon, prostate, endometrial, thyroid, and bladder cancers, and glioblastoma.
  • The review also notes conflicting findings where nesfatin-1 inhibited proliferation in human adrenocortical carcinoma and ovarian epithelial carcinoma cells.
  • The authors propose NUCB2/NESF-1 as a prognostic and predictive marker in cancers.
Limitations: Review article; no original experimental or clinical data.; The abstract summarizes heterogeneous prior studies with conflicting findings.; No quantitative effect estimates are reported in the abstract.; No details on study quality, sample sizes, or methods of the cited studies are provided..

This is a review of a molecule reported to be associated with cancer progression and prognosis, not a primary intervention study.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewMechanismMixed resultsModerate evidenceTier 4 · clinical

Diagnosis and Staging of Bladder Cancer

Hematology/oncology clinics of North America · Jun 2021

bladder cancer

This review summarizes methods for diagnosing and staging bladder cancer. It states that cystoscopy is the diagnostic gold standard, that blue light cystoscopy and narrow band imaging have the strongest evidence among enhanced cystoscopic techniques and should be used if available, that multiparametric MRI may be useful for local staging, and that molecular subtyping could become part of initial histologic staging.

Key findings
  • Cystoscopic examination remains the gold standard technique for initial diagnosis of bladder cancer.
  • Among enhanced cystoscopic techniques, blue light cystoscopy and narrow band imaging are the only ones well supported by high-level evidence and, if available, should be used during initial staging of bladder cancer.
  • Multiparametric MRI could be an important imaging tool in local staging of bladder cancer.
  • Molecular subtyping could become an essential part of initial histologic staging as targeted therapy and immunotherapy options expand.
Limitations: Narrative review article; does not present new primary patient-level data.; Abstract does not provide quantitative performance metrics or direct comparative data between diagnostic modalities..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewTrialReported positiveLimited evidenceTier 3 · early human

Perioperative Immunotherapy in Muscle-invasive Bladder Cancer

European urology oncology · Apr 2021

muscle-invasive bladder cancer (MIBC)metastatic urothelial carcinomaurinary bladder neoplasms

This editorial summarizes that immune checkpoint inhibitors (ICIs), already approved for metastatic urothelial carcinoma, are being investigated as perioperative therapy in muscle-invasive bladder cancer (MIBC). It notes that ongoing trials are testing ICIs both as monotherapy and in combination with other treatments. Early data are described as promising, but the authors state that long-term survival data are still awaited.

Studied with: other treatments.

Key findings
  • Immune checkpoint inhibitors (ICIs) have been approved for metastatic urothelial carcinoma.
  • ICIs are currently being investigated for perioperative treatment of muscle-invasive bladder cancer (MIBC).
  • Ongoing trials are assessing ICIs as monotherapy and in combination with other treatments.
  • Early data are promising, but long-term survival data are awaited to confirm potential in MIBC.
Limitations: Editorial/commentary with no new primary data presented.; No details provided on specific trials, sample sizes, or endpoints.; No quantitative or long-term survival results reported; follow-up data are pending.; Combinations are not specified, limiting actionable interpretation..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewSupportive careInconclusiveLimited evidenceTier 4 · clinical

Bladder Cancer Survivorship

Current urology reports · Nov 2018 · review

Supportive carebladder cancer

This narrative review summarizes recent literature about bladder cancer survivorship, emphasizing quality-of-life impacts and perioperative morbidity, particularly after radical cystectomy. The authors report mixed results in efforts to reduce perioperative morbidity, describe multiple domains of long-term health-related quality-of-life burden (urinary, sexual, financial, psychological), note disparities by race and gender, and conclude there are substantial unmet needs for long-term survivorship support and resources.

Key findings
  • Bladder cancer survivorship is a growing global population with complex, stage- and treatment-dependent needs.
  • Efforts to decrease perioperative morbidity after radical cystectomy have been ongoing but have produced mixed results.
  • There is increasing emphasis on health-related quality of life (HR-QoL) impacts, including urinary function, sexual function, and financial and psychological burden.
  • Validated bladder-cancer-specific HR-QoL measures are available and have helped define the impact and burden of disease.
  • Disparities in oncologic outcomes persist by race and gender.
  • There is an unmet need for long-term support and survivorship resources; outcome-centered perioperative strategies may help reduce treatment morbidity.
Limitations: Narrative review format (the abstract does not state this is a systematic review or meta-analysis), so methods for literature selection are not detailed in the abstract.; No new primary data are reported in this article.; Findings summarized are heterogeneous and described as 'mixed results,' limiting clear conclusions.; Broad scope across many survivorship domains may limit specific, actionable recommendations..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Case reportReported positiveLimited evidenceTier 3 · early humann = 1

Primary undifferentiated sarcoma of the meninges: A case report and comprehensive review of the literature

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · Aug 2018 · case report with comprehensive literature review

primary intracranial undifferentiated (pleomorphic) sarcoma (meningeal)meningeal neoplasmssuperficial bladder cancer (remote history)

This paper reports a case of a 79-year-old man with a primary undifferentiated meningeal sarcoma who underwent surgical excision followed by adjuvant radiotherapy (59.4 Gy over 45 days). Serial brain MRIs up to 27 months after surgery showed no evidence of local recurrence or metastasis. The article also includes a comprehensive literature review summarizing disease hallmarks, diagnostic difficulties, and therapies reported for undifferentiated pleomorphic sarcoma.

Reported effects: adjuvant radiation dose 59.4, n=1 · disease-free follow-up duration 27 mo, n=1

Key findings
  • A 79-year-old man presented with a skull-eroding, enhancing soft tissue lesion; neurosurgical treatment revealed an undifferentiated sarcoma.
  • The patient underwent adjuvant radiation therapy of 59.4Gy fractionated over 45days following surgery.
  • Follow-up brain MRIs at 1-, 6-, 9-, 12-, 15-, 21-, and 27months after surgery have not shown any indications of local recurrence or tumor metastasis.
  • The paper provides a comprehensive literature review summarizing hallmarks, diagnostic challenges, and therapies for undifferentiated pleomorphic sarcoma.
Limitations: Single-patient case report; findings are not generalizable.; Observational retrospective description without control or comparative data.; No systematic assessment of chemotherapy efficacy (minimal data available regarding chemotherapy noted).; Potential publication bias toward unusual or favorable outcomes..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Browse all studies mentioning Bladder Cancer →

Study mix

17 published studies by what they were done in. Lab and animal findings often do not carry over to people.

2 Human15 Review/other
Reported directionReported positive7Mixed results3Inconclusive7

Compounds with reported-positive results in Bladder Cancer

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Preclinical only: lab / animal (1)
Genistein1 positive
Limitations: This article is a narrative review and does not present new clinical trial data.; The evidence summarized is primarily preclinical (in vitro and in vivo) with no clinical trial data provided in the abstract.; Mechanistic proposals are not proven clinical effects and require further experimental and clinical validation.; Safety and efficacy in patients, optimal dosing, and interactions with standard therapies are not established in this review..
Cited positive studies (1)

Evidence at a glance: compounds studied in Bladder Cancer

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

GenisteinInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Biological activities and therapeutic potential of soy isoflavones: a focus on anticancer activity

No human studies yet · No numeric effect sizes reported · Based on a single study.

What the research shows for Bladder Cancer

A plain-language summary of the reviewed studies OncoForge tracks for Bladder Cancer. It reports what those studies described, not a claim that any compound or therapy helps or harms Bladder Cancer. Most of this evidence is early, and findings often conflict.

  • A review of nucleobindin-2/nesfatin-1 (NUCB2/NESF-1) summarizes published reports in several cancers (breast, colon, prostate) that higher expression has been associated with worse outcomes and with increased cancer cell proliferation, migration, and invasion; the review notes conflicting findings across studies and characterizes the overall strength as limited.
  • A narrative review of the adaptor protein CRKL reports that CRKL is overexpressed in many tumor types and is described in the literature as promoting aggressive or malignant behaviors; the authors suggest potential diagnostic or therapeutic interest but rate evidence as limited.
  • Both articles are literature reviews that compile prior preclinical and observational studies (tumor tissue analyses, cell-line work, and some animal data) rather than presenting new randomized clinical-trial evidence.
  • Neither review provides data specific to bladder cancer in the papers supplied here, and the overall findings across the reviewed studies are inconsistent and preliminary.

Supportive & alternative options discussed

  • Hyperthermia (heat): Also discussed as a supportive option for bladder cancer (for example, intravesical therapies combined with local heating), but this set of studies does not provide evidence for or against it.
  • Exercise / prehabilitation: Also discussed as a supportive option to improve general health and quality of life for people with bladder cancer; these reviews do not evaluate exercise interventions.
  • Mind–body (MBSR / CBT): Also discussed as a supportive approach (stress reduction, coping) in cancer care broadly; the provided studies do not address mind–body interventions in bladder cancer.
  • Acupuncture: Also discussed for symptom management (e.g., pain, nausea) in cancer care; the studies provided do not evaluate acupuncture for bladder cancer.
  • Ketogenic / metabolic therapy: Also discussed by some as a complementary dietary approach in cancer, but the reviewed articles do not provide data on ketogenic diets for bladder cancer.
  • Mistletoe (VAE): Also used as an adjunctive therapy by some patients with cancer in certain regions, but the current studies do not present evidence about mistletoe in bladder cancer.

What we don’t know yet

  • Do NUCB2/NESF-1 or CRKL have a role as biomarkers or therapeutic targets specifically in bladder cancer? The provided reviews do not establish this.
  • Are associations reported in other tumor types reproducible in bladder cancer tissue, cell models, or patients? There are no bladder-specific primary studies in these papers.
  • Would modifying NUCB2/NESF-1 or CRKL alter clinical outcomes in patients with bladder cancer? No clinical trials addressing this are reported here.
  • What assays, thresholds, or standardized methods would be needed to measure these proteins reliably in clinical samples? The reviews note variability but do not resolve it.
  • If these proteins were targeted, what dosing, delivery, safety, and long-term effects would be expected? These questions remain unanswered by the reviewed literature.
The evidence summarized in these reviews is preliminary and largely based on preclinical and observational studies in cancers other than bladder; it does not establish clinical relevance or support specific interventions for bladder cancer.

Clinical trials in Bladder Cancer

17 ongoing · 19 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.

Completed
8 stopped (terminated / withdrawn / suspended)

Search all trials on ClinicalTrials.gov →

Getting care & support

Nonprofit / Gov

Practical, vetted help for Bladder Cancer — advocacy, paying for treatment, second opinions, and caregivers.

If you’re struggling emotionally, you don’t have to wait.

Advocacy & community

No dedicated organization for this specific cancer is curated yet — these general organizations can help in the meantime.

Financial help

  • PAN Foundation ↗ — Copay assistance funds by diagnosis (funds open and close as money allows). · status changes often — check the fund’s site
  • HealthWell Foundation ↗ — Copay and premium assistance funds by disease. · status changes often — check the fund’s site
  • CancerCare — financial assistance ↗ — Limited grants plus free financial counseling. · status changes often — check the fund’s site
  • Family Reach ↗ — Help with everyday living costs (rent, transport, food) during treatment. · status changes often — check the fund’s site
  • NeedyMeds ↗ — Searchable directory of drug patient-assistance and discount programs. · status changes often — check the fund’s site
What you’ll typically need to apply
  • Your diagnosis and, if you have it, the specific drug/treatment name (from your care team).
  • Insurance details — your member ID card, or a note that you're uninsured (some funds require active insurance, some don't).
  • Proof of income and household size (recent pay stubs, a tax return, or a benefits letter) — most funds are income-based.
  • Your prescriber's contact information; some programs need the clinic to submit part of the application.
  • Apply early and re-check: funds open and close as money is available, so a closed fund may reopen.

General guidance — each program sets its own eligibility. Confirm requirements on the program’s site.

Help paying for the medicines on this page

Second opinions

Caregiver support

We list only non-profit and government resources — never product sellers — and take no affiliate fees. If a link is broken or a resource doesn't meet that bar, tell us.

Heading to an appointment? Get a printable one-page summary — studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment →